HeartSciences Inc. (HSCS) Earnings History

HeartSciences Inc. - Q2 FY2026 Earnings

Filed at: Dec 14, 2025, 7:00 PM EST|Read from source

EXECUTIVE SUMMARY

HeartSciences reported minimal revenue in its fiscal second quarter of 2026, focusing on the advancement and commercialization of its MyoVista Insights healthcare IT platform and submitting its MyoVista wavECG device for FDA clearance. The company is in commercial discussions for its software platform and anticipates key customer wins.

POSITIVE HIGHLIGHTS

  • •

    MyoVista Insights software is classified as a Medical Device Data System (MDDS), exempt from 510(k) clearance, allowing for faster and less costly commercial rollout.

    positive
  • •

    MyoVista Insights platform is designed to host third-party AI-ECG algorithms, creating an AI-ECG marketplace with a significant market opportunity.

    positive
  • •

    MyoVista wavECG device submitted to the FDA for 510(k) premarket clearance.

    positive

CONCERNS & RISKS

  • •

    Reported no meaningful revenue for FQ2 2026.

    negative
  • •

    As of October 31, 2025, the Company had only $2.0 million in cash and cash equivalents.

    negative
  • •

    The company is still in the early stages of commercialization for its MyoVista Insights platform, with expected customer wins in the near term.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$0.00
N/A
Net Income
Quarterly
N/A
N/A
EPS (Diluted)
Quarterly
N/A
N/A
Operating Income
Quarterly
N/A
N/A
EPS (Basic)
Quarterly
N/A
N/A

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

REVENUE BY SEGMENT — Q2 FY2026 2026

VISUAL OVERVIEW

|
MyoVista Insights Healthcare IT Software
0.0%
N/A
MyoVista wavECG Device
0.0%
N/A

DETAILED BREAKDOWN

|
SegmentCurrentPrior YrYoY% Total
MyoVista Insights Healthcare IT Software
N/A———
MyoVista wavECG Device
N/A———
Total Revenue$0.00M——100.0%

Segment performance shows business unit health and growth drivers.

MANAGEMENT COMMENTARY

MyoVista Insights is a state-of-the-art ECG reporting and management platform that delivers meaningful clinical, operational, and data security benefits for healthcare systems.

— HeartSciences Inc., Q2 FY2026 2026 Earnings Call

In a short period of time, we have received strong validation from early adopters and are actively engaged in commercial discussions with several healthcare institutions.

— HeartSciences Inc., Q2 FY2026 2026 Earnings Call

We expect to announce key customer wins in the near term.

— HeartSciences Inc., Q2 FY2026 2026 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

MyoVista Insights launch date
May 2025
MyoVista wavECG device FDA submission date
FQ2 2026

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.